Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Genetic Modifiers of Cystic Fibrosis Related Diabetes

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2016 by Johns Hopkins University
Cystic Fibrosis Foundation Therapeutics
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
University of Minnesota - Clinical and Translational Science Institute
Northwestern University
Information provided by (Responsible Party):
Scott Blackman, Johns Hopkins University Identifier:
First received: April 28, 2010
Last updated: August 29, 2016
Last verified: August 2016
This research is being done to find the genes and other factors that are responsible for differences among persons with cystic fibrosis. We are particularly interested in the factors that relate to the development of Cystic Fibrosis Related Diabetes (CFRD).

Cystic Fibrosis Related Diabetes

Study Type: Observational
Study Design: Observational Model: Family-Based
Time Perspective: Prospective
Official Title: Genetic Modifiers of Cystic Fibrosis Related Diabetes

Resource links provided by NLM:

Further study details as provided by Johns Hopkins University:

Primary Outcome Measures:
  • Identification of Genes or other factors that influence the development of CFRD [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA
Blood will be drawn from study participants and their parents. Two tablespoons of blood (one tablespoon in small children) will be drawn by standard techniques from a vein in the arm. Whenever possible, blood samples for this study will be collected at the same time that it is done for medically needed blood tests. This blood will be used to extract DNA and to establish cell lines that we will store as a permanent source of DNA. We will compare your clinical symptoms with your DNA to see if additional genes that affect CF symptoms can be found. Some serum and plasma will be stored for later testing, as additional knowledge becomes available. Any tests done in the future with your stored blood samples or your DNA will only be to answer questions about genes for CF.

Estimated Enrollment: 1500
Study Start Date: April 2008
Estimated Study Completion Date: April 2020
Estimated Primary Completion Date: April 2020 (Final data collection date for primary outcome measure)
Detailed Description:
The study is recruiting people with cystic fibrosis (CF). The medical record is being extracted, and a blood sample is taken for DNA. The DNA samples are tested for variation both at the CFTR gene (the CF gene) and over the entire rest of the genome. Using large numbers of people with CF, and knowing who does and does not have CFRD, we identify genetic variations that associate with CFRD. Knowing these variations allows us to better understand the causes of CFRD, and with enough information, better to predict CFRD and identify people at particularly high or low risk of CFRD. People participating in this study also have the option to participate in related studies of other metabolic traits in CF such as over- and underweight.

Ages Eligible for Study:   3 Months to 99 Years   (Child, Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Individuals affected with Cystic Fibrosis and family members

Inclusion Criteria:

  • Any person with Cystic Fibrosis and his/her parents.

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01113216

United States, Illinois
Children's Memorial Hospital Not yet recruiting
Chicago, Illinois, United States
Contact: Susanna McColley, MD   
United States, Maryland
Johns Hopkins Medicine Recruiting
Baltimore, Maryland, United States, 21287
Contact: Scott M Blackman, MD, PhD    410-955-6463   
Contact: Karen S Raraigh, MS    410-502-7124   
United States, Minnesota
University of Minnesota Not yet recruiting
Minneapolis, Minnesota, United States
Contact: Antoinette Moran, MD   
Sponsors and Collaborators
Johns Hopkins University
Cystic Fibrosis Foundation Therapeutics
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
University of Minnesota - Clinical and Translational Science Institute
Northwestern University
Principal Investigator: Scott M Blackman, MD, PhD Johns Hopkins Medicine
  More Information

Responsible Party: Scott Blackman, Assistant Professor, Johns Hopkins University Identifier: NCT01113216     History of Changes
Other Study ID Numbers: CFF-CFRD01  K23DK083551 
Study First Received: April 28, 2010
Last Updated: August 29, 2016
Health Authority: United States: Institutional Review Board
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by Johns Hopkins University:
Genetic Modifiers

Additional relevant MeSH terms:
Cystic Fibrosis
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases processed this record on October 26, 2016